Cilostazol and Brugada Syndrome. We report the case of 67-year-old man with Brugada syndrome, in whom daily episodes of ventricular brillation (VF) occurred every early morning for 4 days. The episodes of VF were completely prevented by an oral administration of cilostazol, a phosphodiesterase inhibitor. This effect was con rmed by the on-and-off challenge test, in which discontinuation of the drug resulted in recurrence of VF and resumption of the drug again prevented VF. This effect may be related to the suppression of I to secondary to the increase in heart rate and/or to an increase in Ca 21 current (I C a ) due to an elevation of intracellular cyclic AMP concentration via inhibition of phosphodiesterase activity. This drug might have an anti-VF potential in patients with Brugada
Introduction
Brugada syndrome is characterized by an ECG pattern of right bundle branch block and ST segment elevation in leads V 1 through V 3 . 1 -4 Isoproterenol is reported to be effective in normalizing ST segment elevation, leading to suppression of ventricular brillation (VF) via enhancement of inward Ca 2 current (I Ca ). 3 However, to date there is no report on effective oral drugs to be used for prevention of VF in patients with Brugada syndrome. 4 -7 Cilostazol, an oral phosphodiesterase type III inhibitor, is known to increase I Ca and heart rate by elevating the level of intracellular cyclic AMP via an inhibitory effect on phosphodiesterase activity. 8 ,9 We report the case of a patient with Brugada syndrome in whom daily episodes of VF were completely prevented by oral administration of cilostazol.
Case Report A 67-year-old man was admitted to our hospital because of frequent episodes of convulsion during sleep. Twelve-lead ECG showed sinus rhythm with transient ST segment elevation in leads V 2 through V 4 associated with a right bundle branch block pattern (Fig. 1) . QT interval was normal. Extensive investigation, which included echocardiography, left and right ventriculography, coronary angiography, and biopsy specimen obtained from the right ventricular septum, did not show any structural heart disease. The late potential was considered to be positive. Brugada syndrome was diagnosed after documentation of VF during convulsion. Continuous intravenous infusion of isoproterenol completely suppressed the occurrence of VF.
After obtaining written informed consent, electrophysiologic study using a standard technique was performed 1 day later. The study was performed with the patient in a nonsedated condition and without any antiarrhythmic agents. Sinus node recovery time, AV nodal function, and HV interval were all normal. VF was induced with triple extrastimuli applied to the right ventricular apex. Intravenous application of pilsicainide, a Class IC antiarrhythmic drug, at a dose of 0.1 mg/kg led to augmentation of ST elevation in leads V 1 through V 3 (Fig. 2) . 6 Fig. 3) . He was readmitted to our hospital on February 6. The electrograms stored in the ICD and the ECG recordings obtained from Holter ECG or heart monitor revealed that sinus bradycardia with a mean cycle length of 1,123 6 102 msec preceded the episodes of VF, which were effectively terminated with 30-J DC shock. Premature ventricular contractions showing QRS morphology similar to the premature ventricular beat that triggered VF were observed frequently before VF occurrence (Fig. 3) .
On February Table 1 shows the minimal heart rate, total beat counts, and number of premature ventricular contractions for every hour from 12:00 A.M. to 7:00 A.M. for each Holter ECG recording. It is evident that cilostazol increased both the minimal heart rate and total beat count during early morning and abolished the occurrence of VF. There was no difference in the number of premature ventricular contractions among the various conditions.
Discussion
This is the rst report to describe a patient with Brugada syndrome in whom daily VFs were completely prevented by oral administration of cilostazol, a phosphodiesterase type III inhibitor.
Brugada syndrome is suggested to be a primary electrical disease, and mutations in the cardiac sodium channel gene SCN5A have been found in patients with the familial form of the disease. 1 0 -1 2 The ionic and cellular basis for ST segment elevation in Brugada syndrome is hypothesized to be due to an outward shift in the balance of the membrane ionic currents at the end of phase 1 and phase 2 of the action potential, in which an outward current is mainly due to activation of the transient outward current I to and the inward current is mainly due to the activation of I Ca and an inactivating component of I Na . 3 ,1 2 The net outward shift of this current balance leads to loss of the dome or phase 2 of the action potential. 1 2 Such changes may affect the right ventricular epicardium more markedly than the endocardium. These changes produce a marked voltage gradient in the membrane potential between the endocardial and epicardial sides of the right ventricular muscle bers during phase 2 (a change corresponding to the characteristic ST segment elevation in leads V 1 through V 3 seen on the ECGs of patients with Brugada syndrome). They also produce nonuniform repolarization in some restricted areas of the ventricular myocardium, a good substrate for the development of reentrant arrhythmias. 1 2 A variety of pathophysiologic conditions and pharmacologic interventions that either increase the membrane outward currents or reduce the inward currents should produce loss of the action potential dome in the right ventricular epicardium and facilitate the occurrence of VF. 1 2 Phase 2 of the action potential could be abolished by reducing inward Na current as predicted by the ST segment elevation after application of pilsicainide (cf. Fig. 2 , arrows) 6 and restored by increasing the inward current, e.g., by enhancing I Ca (present study) or by decreasing the outward I to current, e.g., by application of quinidine as reported. 1 2 Isoproterenol is known to be especially effective in suppressing ST elevation on leads V 1 through V 3 in patients with Brugada syndrome and restoring the action potential dome in the models of this syndrome, because it markedly increases I Ca secondary to elevation of intracellular levels of cyclic AMP. 3 ,1 2 It also has been reported that DDD pacing at a relatively high rate is effective in decreasing I to (and hence suppressing VF), possibly because the repriming time of I to channels is reported to be fairly long. 7 Quinidine, a vagolytic Class I antiarrhythmic agent that blocks I to , is known to be able to restore the action potential dome, normalize ST segment abnormality, and prevent the occurrence of VF in experimental models of this syndrome. 1 2 However, to date there is no convincing report on oral drug treatment for VF in patients with Brugada syndrome.
Cilostazol, a new phosphodiesterase type III inhibitor, is used primarily as a strong antiplatelet agent, but it has been shown to increase I Ca 9 and modestly increase heart rate 8 and contractive function. 9 All of these effects were secondary to an increased level of cyclic AMP caused by inhibition of phosphodiesterase type III activity in guinea pig ventricular myocytes and papillary muscles. 9 Based on these ndings and our present observations, it is reasonable to believe that this drug has antiarrhythmic ef cacy for preventing VFs often seen in patients with Brugada syndrome, because it increased I Ca by inhibiting phosphodiesterase activity in the ventricular myocyte and decreased I to by increasing heart rate, which again was secondary to increased I Ca in the sinus node. It is possible that the recurrent episodes in this patient represent a spontaneous cluster because these VF storms occur in patients with primary electrical disease.
In conclusion, cilostazol was administered for frequent VFs occurring in a patient with Brugada syndrome. The drug was found to be very effective in preventing VF. The favorable action of cilostazol is attributed to (1) enhanced I Ca followed by restoration of the action potential dome (phase 2) and subsequent abolition of nonuniform repolarization, and (2) indirect suppression of I to due to increased heart rate (cf. Table 1 ) in a particular part of the right ventricular myocardium. Therefore, cilostazol might be useful in preventing the occurrence of VF, an event often encountered in patients with Brugada syndrome. However, further studies are needed to establish the clinical usefulness of this drug for prevention of ventricular tachyarrhythmias related to Brugada syndrome.
